0000899243-18-026783.txt : 20181016
0000899243-18-026783.hdr.sgml : 20181016
20181016160046
ACCESSION NUMBER: 0000899243-18-026783
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181012
FILED AS OF DATE: 20181016
DATE AS OF CHANGE: 20181016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lurker Nancy
CENTRAL INDEX KEY: 0001450485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 181124493
MAIL ADDRESS:
STREET 1: PDI, INC.
STREET 2: 1 ROUTE 17 SOUTH
CITY: SADDLE RIVER
STATE: NJ
ZIP: 07458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-12
0
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001450485
Lurker Nancy
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
1
1
0
0
President & CEO
Common Stock
2018-10-12
4
A
0
76667
0.00
A
211700
D
On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 38,334 shares representing a previously granted performance stock unit award vested on that date. An additional 38,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
/s/ John Mercer, Attorney-in-Fact
2018-10-16